- Home
- EDRY vs INKT Comparison
EDRY vs INKT Comparison
Compare EDRY & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | INKT |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 59.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDRY | INKT |
|---|---|---|
| Price | $69.61 | $11.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 161.0K | 11.5K |
| Earning Date | 06-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $8.48 |
| 52 Week High | $73.07 | $16.80 |
Technical Indicators
Market Signals| Indicator | EDRY | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 73.41 | 52.38 |
| Support Level | $17.86 | $10.82 |
| Resistance Level | N/A | $12.04 |
| Average True Range (ATR) | 5.29 | 0.52 |
| MACD | 0.64 | -0.01 |
| Stochastic Oscillator | 84.93 | 47.06 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.